Evidence map›Paper›PMID 28632992›Full record

ReviewSmall GTPases2020

Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers.

Jordan M Thompson, Jaime Landman, Olga V Razorenova

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Small GTPases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jordan M ThompsonMolecular Biology and Biochemistry Department, University of California Irvine, Irvine, CA, USA.
Jaime LandmanUrology Department, School of Medicine, University of California Irvine, Irvine, CA, USA.
Olga V RazorenovaMolecular Biology and Biochemistry Department, University of California Irvine, Irvine, CA, USA.
University of California, Irvine · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
NCATS NIH HHS UL1 TR001414NCI NIH HHS T32 CA009054
6 · The paper itself

Abstract

The loss of the von Hippel-Lindau (

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsHumansMolecular Targeted TherapyNeoplasmsrho-Associated Kinasesrho GTP-Binding ProteinsVon Hippel-Lindau Tumor Suppressor ProteinBasic Helix-Loop-Helix Proteinsrho-Associated Kinasesrho GTP-Binding ProteinsVon Hippel-Lindau Tumor Suppressor ProteinClear Cell Renal Cell CarcinomaHIFRhoROCK1synthetic lethalityVHL

Identifiers

PMID28632992
PMCPMC6959287
OpenAlexW2692443884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.